Want real case studies? 10 seconds to sign up
Join the platform
Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
December 18, 2025
Approximately 5 minutes
EUDAMED Mandatory Timeline: Essential Insights from the Brussels Workshop
The European Commission’s recent workshop in Brussels confirmed a pivotal shift for medical device regulation in Europe. Following Commission Decision 2025/2371, EUDAMED has met its functional specifications, triggering the countdown for mandatory compliance under MDR Article 123.
Critical Deadlines
The transition to mandatory usage follows a tiered schedule. Organizations must be ready for the following dates:
- 28 May 2026: Modules for Actors, Devices, and Market Surveillance become fully mandatory.
- 28 May 2027: The Certificates module becomes mandatory. However, any certificate issued after May 2026 must be entered into the system immediately.
The Registration Hierarchy
Registration in EUDAMED must follow a strict, logical sequence. You cannot skip steps:
- Actors: Register the organization and legal entities.
- Devices: Register product data and UDI-DI.
- Certificates: Link approved certificates to registered devices.
- Vigilance: Enter incident reports and safety data.
Actor Registration and Management
To access EUDAMED, users must first establish an EU Login. Every actor is required to appoint at least two Local Actor Administrators (LAA).
- LAA Role: The only users authorized to change organizational data.
- LUA Role: Local User Administrators can be appointed by the LAA to manage general user roles and access permissions.
Playground vs. Production
EUDAMED operates in two distinct environments:
- Playground: Used strictly for training and testing procedures. Data entered here is fictional and cannot be transferred to the live system.
- Production: The live environment for real regulatory data. While drafts can be saved, once a record is confirmed, it is final. Corrections usually require a new version or a formal deletion request via the EUDAMED Desk.
Devices and Market Surveillance
- Basic UDI-DI: This serves as the identifier for a device family. Manufacturers can link multiple UDI-DIs to a single Basic UDI-DI, but legacy devices are limited to a one-to-one link between EUDAMED DI and ID.
- Market Surveillance Triggers: The module is primarily for authorities and notified bodies. Triggers for procedures include Manufacturer Incident Reports, FSCAs, and complaints. Notably, PSURs and trend reports are currently excluded as triggers.
Next Steps: Manufacturers should immediately begin training in the Playground environment, appoint their LAAs, and prepare their internal procedures for device data entry before the May 2026 deadline.
Registered Pharmacist · AI Engineer · Director, ElendiLabs
Registered pharmacist, AI engineer, HKHAIS founder, and pharmaceutical & medical device SEO/GEO specialist.
Ask Anything
We'll follow up with you personally.
100% response rate • Reply within 7 business days
Related Articles
Approximately 5 minutes
Global MedTech Compliance: A Comparative Analysis of EU-MDR and UK MHRA Frameworks (2026)
An expert synthesis of the regulatory landscape in 2026, comparing the clinical-heavy requirements of EU-MDR with the pragmatic, reliance-based pathways of the UK MHRA.
Approximately 5 minutes
Master Technical Documentation under MDR 2017/745
Technical Documentation (TD) is more than just paperwork; it is the foundation of your device's identity and proof of conformity with MDR 2017/745. This article explores the 'Iceberg' of TD, breaking down the 7 essential pillars from GSPR to Post-Market Surveillance. Learn how to apply the 3Cs—Clarity, Consistency, and Connectivity—to ensure faster Notified Body reviews and a safer time to market.
Approximately 5 minutes
MDCG Guidance: Navigating the 'Best Practice' Landscape of EU MDR
The Medical Device Coordination Group (MDCG) has published over 70 guidance documents since the MDR came into force. While not legally binding legislation, these papers represent the EU Commission's 'best practice' and are used by Notified Bodies to justify audit findings. This article explores the significance of MDCG documents, their role in conformity assessments, and why manufacturers must integrate them into their compliance strategy.
Approximately 5 minutes
Bridging the Gap: EU vs. US Clinical Evidence Requirements for Medical Devices
Navigating the clinical evidence requirements of the EU MDR and the US FDA often catches companies off-guard. While the EU focuses on the Clinical Evaluation Report (CER) and GSPR alignment, the FDA relies on a risk-driven approach involving PMAs and 510(k) substantial equivalence. This article explores how ISO 14155 serves as a common language for both regions and highlights common weaknesses in clinical strategies that lead to regulatory rework.
Approximately 5 minutes
EU Commission to Harmonize Notified Body Procedures: Predictability in Sight
The European Commission is developing a new implementing regulation to address the unpredictability of medical device and IVD conformity assessments. Currently, significant variations in timelines and costs among Notified Bodies cause delays that impact patient care. This new law will require Notified Bodies to publish clear review timelines, define 'clock stoppers,' and provide transparent cost breakdowns for certification and surveillance activities.